CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy
Authors:
- Steven P. WolfSWSteven P. Wolf
- Matthias LeisegangMLMatthias Leisegang
- Madeline SteinerMSMadeline Steiner
- Veronika WallaceVWVeronika Wallace
- Kazuma KiyotaniKKKazuma Kiyotani
- Yifei HuYHYifei Hu
- Jun HuangJHJun Huang
- Karin SchreiberKSKarin Schreiber
- Yusuke NakamuraYNYusuke Nakamura
- Andrea SchietingerASAndrea Schietinger
- Hans SchreiberHSHans Schreiber
- 13 September 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (99) , eadp6529
Abstract
Cancers eventually kill hosts even when infiltrated by cancer-specific T cells. We examined whether cancer-specific T cell receptors of CD4 + T cells (CD4TCRs) from tumor-bearing hosts can be exploited for adoptive TCR therapy. We focused on CD4TCRs targeting an autochthonous mutant neoantigen that is only presented by stroma surrounding the MHC class II–negative cancer cells. The 11 most common tetramer-sorted CD4TCRs were tested using TCR-engineered CD4 + T cells. Three TCRs were characterized by convergent recombination for which multiple T cell clonotypes differed in their nucleotide sequences but encoded identical TCR α and β chains. These preferentially selected TCRs destroyed tumors equally well and halted progression through reprogramming of the tumor stroma. TCRs represented by single T cell clonotypes were similarly effective only if they shared CDR elements with preferentially selected TCRs in both α and β chains. Selecting candidate TCRs on the basis of these characteristics can help identify TCRs that are potentially therapeutically effective.Keywords
This publication has 77 references indexed in Scilit:
- CD4+ T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse modelsCancer Immunology, Immunotherapy, 2019
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinomaJournal of Hepatology, 2019
- Tumor mechanisms of resistance to immune attack2019
- Indirect CD4+ T‐cell‐mediated elimination of MHC IINEG tumor cells is spatially restricted and fails to prevent escape of antigen‐negative cellsEuropean Journal of Immunology, 2014
- Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex AffinityCancer Cell, 2013
- Suppression of T-cell responses by tumor metabolitesCancer Immunology, Immunotherapy, 2011
- A clonotype nomenclature for T cell receptorsImmunogenetics, 2009
- Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapyTrends in Immunology, 2005
- A unique tumor antigen produced by a single amino acid substitutionImmunity, 1995